publication venue for Response to Osimertinib in an EGFR Exon 20 insertion-positive lung adenocarcinoma 2018 Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer 2008
